InsuLine Medical Ltd. (TASE: INSL) will conduct a premarketing clinical trial of its InsuPad insulin delivery patch at the Diabetes Research Institute in Bad Mergentheim, Germany. The study will test the effectiveness of the product
The Diabetes Research Institute treats 12,000 diabetics a year.
The objective of the study to demonstrate the InsuPad's ability to control of blood sugar levels after meals by insulin injections before eating. 40 patients with type 1 and type 2 diabetes will participate in the study
InsuLine chairman Ilan Cohen said, "This is an important strategic achievement for InsuLine in penetrating the German market. It follows our previous steps in this market."
InsuLine's share price rose 1% by mid-afternoon to NIS 1.17, giving a market cap of NIS 67 million.
Published by Globes [online], Israel business news - www.globes-online.com - on January 18, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011